Post-COVID-19 Illness Trend in a Local Community in Bangladesh.
clinical symptoms
covid-19
old age
post-covid symptoms
risk factors
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
Sep 2023
Sep 2023
Historique:
accepted:
26
09
2023
medline:
30
10
2023
pubmed:
30
10
2023
entrez:
30
10
2023
Statut:
epublish
Résumé
An infection with coronavirus disease 2019 (COVID-19) might show a wide range of symptoms. Many individuals still experience symptoms after a prolonged period of initial COVID-19. The objective is to find out the prolonged consequences of COVID-19 with their associations. Two hundred and eighty-six COVID-19 cases were the subject of this cross-sectional investigation, which was carried out in basic and secondary healthcare facilities in Bangladesh. COVID-19-positive participants with consent were interviewed in person about their sociodemographic traits, the nature of their COVID-19 infection, risk factors, present manifestations, etc. We carried out our statistical exploration by use of IBM SPSS Statistics for Windows, Version 22 (Released 2013; IBM Corp., Armonk, New York, United States). To evaluate differences, we utilized the chi-square (χ2) test as well as the unpaired t-test. Our significance threshold level was 0.05. In this study, 18.5% of participants reported having post-COVID-19 symptoms. The four main symptom categories were anorexia (26.4%), myalgia (34.8%), fatigue (41.5%), and palpitations (25.5%). The majority of post-COVID-19 syndrome patients (e.g., 40.0%) were over 50 years old. Severe disease (81.8%) was more likely to develop post-COVID-19 illness. Fifty-three out of 286 participants (or 18.5%) reported having post-COVID-19 symptoms. The main symptom categories included fatigue, myalgia, anorexia, and palpitations. In order to determine the risk variables our data supports, additional investigation is required.
Sections du résumé
BACKGROUND
BACKGROUND
An infection with coronavirus disease 2019 (COVID-19) might show a wide range of symptoms. Many individuals still experience symptoms after a prolonged period of initial COVID-19.
OBJECTIVES
OBJECTIVE
The objective is to find out the prolonged consequences of COVID-19 with their associations.
MATERIALS AND METHOD
METHODS
Two hundred and eighty-six COVID-19 cases were the subject of this cross-sectional investigation, which was carried out in basic and secondary healthcare facilities in Bangladesh. COVID-19-positive participants with consent were interviewed in person about their sociodemographic traits, the nature of their COVID-19 infection, risk factors, present manifestations, etc. We carried out our statistical exploration by use of IBM SPSS Statistics for Windows, Version 22 (Released 2013; IBM Corp., Armonk, New York, United States). To evaluate differences, we utilized the chi-square (χ2) test as well as the unpaired t-test. Our significance threshold level was 0.05.
RESULT
RESULTS
In this study, 18.5% of participants reported having post-COVID-19 symptoms. The four main symptom categories were anorexia (26.4%), myalgia (34.8%), fatigue (41.5%), and palpitations (25.5%). The majority of post-COVID-19 syndrome patients (e.g., 40.0%) were over 50 years old. Severe disease (81.8%) was more likely to develop post-COVID-19 illness.
CONCLUSION
CONCLUSIONS
Fifty-three out of 286 participants (or 18.5%) reported having post-COVID-19 symptoms. The main symptom categories included fatigue, myalgia, anorexia, and palpitations. In order to determine the risk variables our data supports, additional investigation is required.
Identifiants
pubmed: 37900461
doi: 10.7759/cureus.45998
pmc: PMC10601977
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e45998Informations de copyright
Copyright © 2023, Hossain et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
EClinicalMedicine. 2021 Aug;38:101019
pubmed: 34308300
Diagnosis (Berl). 2020 May 26;7(2):91-96
pubmed: 32352401
Nat Med. 2021 Apr;27(4):626-631
pubmed: 33692530
Pan Afr Med J. 2021 Jan 20;38:65
pubmed: 33889231
Int J Environ Res Public Health. 2021 Mar 05;18(5):
pubmed: 33807869
Lancet. 2021 Jan 16;397(10270):220-232
pubmed: 33428867
J Infect Dis. 2020 May 11;221(11):1757-1761
pubmed: 32067043
Int J Infect Dis. 2020 May;94:128-132
pubmed: 32251805
J Virol. 2009 Apr;83(7):3039-48
pubmed: 19004938
Lancet Infect Dis. 2020 May;20(5):534-535
pubmed: 32119823
Int J Environ Res Public Health. 2021 Feb 05;18(4):
pubmed: 33562427
Epidemiol Infect. 2020 Sep 03;148:e199
pubmed: 32878654
MMWR Morb Mortal Wkly Rep. 2020 Apr 10;69(14):411-415
pubmed: 32271722
Proc Natl Acad Sci U S A. 2012 Jun 19;109(25):9983-8
pubmed: 22665800
BMJ. 2020 Sep 7;370:m3489
pubmed: 32895219
Lancet Infect Dis. 2020 Apr;20(4):410-411
pubmed: 32087116
JAMA Netw Open. 2021 Feb 1;4(2):e210830
pubmed: 33606031
PLoS One. 2021 Apr 8;16(4):e0249644
pubmed: 33831043
Travel Med Infect Dis. 2020 Mar - Apr;34:101623
pubmed: 32179124
BMJ Glob Health. 2021 Dec;6(12):
pubmed: 34906986
Clin Immunol. 2020 Jun;215:108427
pubmed: 32325252
BMC Med. 2021 Mar 31;19(1):84
pubmed: 33785027